NCT06020001

Clinical Evaluation of the AP203 Plant Extract Mixture in Adult Patients With Increased Incidence of Viral and/or Bacterial Upper Respiratory Tract Infections

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: AronPharma Sp. z o. o. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The aim of the study was to assess the efficacy and safety of AP203 preparation (RESCOVIN®) in a group of patients with increased incidence to viral and/or bacterial upper respiratory tract infections.

Detailed description

Randomized, double-blind, cross over study conducted under medical supervision on 1) group of 30 patients receiving AP203 mixture in capsule form and 2) group of 30 receiving placebo. After a washout period a group receiving placebo receiver AP203 mixture in syrup form. The study group was adult patients with an increased incidence of upper respiratory tract infection. During the study, the effect of a mixture of AP203 extracts (RESCOVIN®) on markers of inflammation and oxidative stress and the effect on the incidence of upper respiratory tract infections was assessed.

Conditions

• Upper Respiratory Tract Infection Bacterial

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	AP203 mixture (RESCOVIN®)	Polyphenol-rich plant extracts Twice a day
DIETARY_SUPPLEMENT	AP203 mixture (RESCOVIN®)	Polyphenol-rich plant extracts Twice a day
OTHER	Placebo	Twice a day

Timeline

• Start date: 2022-10-14
• Primary completion: 2023-04-27
• Completion: 2023-04-27
• First posted: 2023-08-31
• Last updated: 2023-09-11

Locations

1 site across 1 country: Poland